Skip to main content
. 2022 Oct 7;20(12):2921–2929. doi: 10.1111/jth.15883

FIGURE 1.

FIGURE 1

Six‐month cumulative incidence of venous, arterial, and any thromboembolic events in patients with cancer initiating treatment with immune checkpoint inhibitors